Patrice K Held1, Christopher A Haynes2, Víctor R De Jesús2, Mei W Baker3. 1. Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, WI 53706, United States; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States. Electronic address: patrice.held@slh.wisc.edu. 2. Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Atlanta, GA 30341, United States. 3. Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, WI 53706, United States; Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
Abstract
BACKGROUND: Orotic aciduria in the presence of hyperammonemia is a key indicator for a defect in the urea cycle, specifically ornithine transcarbamylase (OTC) deficiency. Current newborn screening (NBS) protocols can detect several defects of the urea cycle, but screening for OTC deficiency remains a challenge due to the lack of a suitable assay. The purpose of this study was to develop a high-throughput assay to measure orotic acid in dried blood spot (DBS) specimens as an indicator for urea cycle dysfunction, which can be readily incorporated into routine NBS. METHODS: Orotic acid was extracted from DBS punches and analyzed using flow-injection analysis tandem mass spectrometry (FIA-MS/MS) with negative-mode ionization, requiring <2 min/sample run time. This method was then multiplexed into a conventional newborn screening assay for analysis of amino acids, acylcarnitines, and orotic acid. RESULTS: We describe 2 assays which can quantify orotic acid in DBS: a stand-alone method and a combined method for analysis of orotic acid, amino acids, and acylcarnitines. Both methods demonstrated orotic acid recovery of 75-85% at multiple levels of enrichment. Precision was also comparable to traditional FIA-MS/MS methods. Analysis of residual presumptively normal NBS specimens demonstrated a 5:1 signal to noise ratio and the average concentration of orotic acid was approximately 1.2 μmol/l. The concentration of amino acids and acylcarnitines as measured by the combined method showed no significant differences when compared to the conventional newborn screening assay. In addition, retrospective analysis of confirmed patients and presumptively normal newborn screening specimens suggests potential for the methods to identify patients with OTC deficiency, as well as other urea cycle defects. CONCLUSION: The assays described here quantify orotic acid in DBS using a simple extraction and FIA-MS/MS analysis procedures that can be implemented into current NBS protocols.
BACKGROUND:Orotic aciduria in the presence of hyperammonemia is a key indicator for a defect in the urea cycle, specifically ornithine transcarbamylase (OTC) deficiency. Current newborn screening (NBS) protocols can detect several defects of the urea cycle, but screening for OTC deficiency remains a challenge due to the lack of a suitable assay. The purpose of this study was to develop a high-throughput assay to measure orotic acid in dried blood spot (DBS) specimens as an indicator for urea cycle dysfunction, which can be readily incorporated into routine NBS. METHODS:Orotic acid was extracted from DBS punches and analyzed using flow-injection analysis tandem mass spectrometry (FIA-MS/MS) with negative-mode ionization, requiring <2 min/sample run time. This method was then multiplexed into a conventional newborn screening assay for analysis of amino acids, acylcarnitines, and orotic acid. RESULTS: We describe 2 assays which can quantify orotic acid in DBS: a stand-alone method and a combined method for analysis of orotic acid, amino acids, and acylcarnitines. Both methods demonstrated orotic acid recovery of 75-85% at multiple levels of enrichment. Precision was also comparable to traditional FIA-MS/MS methods. Analysis of residual presumptively normal NBS specimens demonstrated a 5:1 signal to noise ratio and the average concentration of orotic acid was approximately 1.2 μmol/l. The concentration of amino acids and acylcarnitines as measured by the combined method showed no significant differences when compared to the conventional newborn screening assay. In addition, retrospective analysis of confirmed patients and presumptively normal newborn screening specimens suggests potential for the methods to identify patients with OTC deficiency, as well as other urea cycle defects. CONCLUSION: The assays described here quantify orotic acid in DBS using a simple extraction and FIA-MS/MS analysis procedures that can be implemented into current NBS protocols.
Authors: Mohamed S Rashed; Minnie Jacob; Mohamed Al-Amoudi; Zuhair Rahbeeni; Moeen A D Al-Sayed; Lujane Al-Ahaidib; Amal A A Saadallah; Sharon Legaspi Journal: Clin Chem Date: 2003-03 Impact factor: 8.327
Authors: Johannes Sander; Nils Janzen; Stefanie Sander; Ulrike Steuerwald; Anibh M Das; Sabine Scholl; Friedrich K Trefz; Hans-Georg Koch; Johannes Häberle; Herbert Korall; Iris Marquardt; Christoph Korenke Journal: Eur J Pediatr Date: 2003-04-08 Impact factor: 3.183
Authors: Nils Janzen; Michael Terhardt; Stefanie Sander; Mübeccel Demirkol; Gülden Gökçay; Michael Peter; Thomas Lücke; Johannes Sander; Anibh M Das Journal: Clin Chim Acta Date: 2013-12-25 Impact factor: 3.786